ALPMF News and Press, Astellas Pharma Inc From 07/09/21

The U.S. FDA has granted Astellas Pharma ([[ALPMF]]) and Seagen's ([[SGEN]] -0.4%) PADCEV (enfortumab vedotin-ejfv) expanded approval for a new indication to treat certain patients with urothelial cancer.The approval allows for the use of PADCEV for adult patients with locally advan...

AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...

The European Commission ((EC)) has approved an additional indication for Astellas Pharma's (ALPMF) oral once-daily therapy Xtandi (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC). The...

Astellas Pharma, Inc. (ALPMF) Q4 2021 Earnings Conference Call April 27, 2021 1:00 AM ET Company Participants Kenji Yasukawa - President & CEO Naoki Okamura - Corporate EVP, Chief Strategy Officer and CFO Yukio Matsui - Chief Commercial Officer Bernie Zeiher - Chief Medical Officer Confer...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Astellas Pharma Inc. 2020 Q4 - Results - Earnings Call Presentation

Astellas Pharma (ALPMF): FY Non-GAAP core basic EPS of ¥113.03; GAAP Diluted EPS of ¥64.90.Revenue of ¥1249.53B (-3.9% Y/Y)Press Release For further details see: Astellas Pharma reports FY results

Under Real-Time Oncology Review ((RTOR)) pilot program, FDA has accepted for review Seagen (SGEN) and Astellas Pharma's (ALPMF) two supplemental Biologics License Applications (sBLA) for PADCEV (enfortumab vedotin-ejfv) in locally advanced or metastatic urothelial cancer.The applications...

Astellas Pharma (ALPMF) announces that a Phase 3 confirmatory trial of Xospata (gilteritinib) in patients with relapsed or refractory FLT3 mutation-positive acute myeloid leukemia ((AML)) met its primary endpoint of overall survival ((OS)) compared to chemotherapy at a planned interim an...

Astellas Pharma ([[ALPMF]]) announced that the FDA has approved Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) for neurogenic detrusor overactivity (“NDO”) in children aged three years and older.The d...

The EMA has accepted Astellas Pharma (ALPMF) and Seagen's (SGEN) marketing authorization application ((MAA)) for enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor and a platinum-containing ...